Conference Speakers
Cultural Speakers
Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.
At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:
X
Dr. Speakers Full Name
Speaker Credentials
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization and in 2008 sat for and passed the exam administered by the International Board of Lactation Consultant Examiners. As an International Board Certified Lactation Consultant, she now
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization text text text text more name mulder first became interested in breastfeeding in the year 2000, when she became.
X
Abstract: Breastfeeding mothers may turn to formula and/or bottles for many
reasons. Some supplementing with formula by bottle when they reach out for help, and for some moms,
supplementing by alternative methods may be very overwhelming. Some moms need or choose a combination
of breast milk and formula and others may decide to give occasional or regular bottles of expressed
milk. Whatever the reason, as health care professionals helping a mother to breastfeed, it is our
job to be able to help her to reach her own personal goals even when she needs, or chooses to use,
bottles or formula. Learn about baby-led bottle feeding and why it's so important, different types
of formula, their uses and how to prepare them, and how this all fits in with the WHO code and our
code of professional conduct.
View Full Presentation Information & Scheduling
Dr. Speakers Full Name
Speaker Credentials
Speakers (5191)
CSO and Thoracic Medical oncologist
Published in
Speakers
Dr. Jonathan Spicer is an assistant professor of surgery at McGill University, where he is the medical director of the McGill University Health Center (MUHC) Thoracic Oncology Network. He chairs the McGill regional thoracic oncology tumor board and is co-director of the MUHC thoracic oncology clinical trials unit. Dr. Spicer is a surgeon scientist leading a broad research program covering basic, translational and clinical research topics. He trained in general surgery at McGill University and subsequently in cardiothoracic surgery at the University of Texas, MD Anderson Cancer Centre. On a basic science front, Dr. Spicer is recognized as a leader in our understanding of how neutrophils impact cancer progression, and in particular, on the role of neutrophil extracellular traps in cancer biology. On a clinical front, Dr. Spicer has developed one of the most active research programs in the area of neoadjuvant immunotherapy for operable lung cancer. He is an expert in surgical enhanced recovery protocols and his clinical practice is focused on minimal access techniques for pulmonary surgery and extended resections for thoracic malignancies. He is the program director for the McGill Advanced Thoracic and Upper GI Surgical Oncology Fellowship. Dr. Spicer is the research chair for the Canadian Association of Thoracic Surgeons, director of the Canadian Cancer Trials Mesothelioma Working Group and sits on numerous steering committees for phase 2 and 3 international trials investigating the use of novel therapies prior to lung cancer resections.
Published in
Speakers
Dr Skoulidis obtained a Medical Degree from the Aristotle University of Thessaloniki, Greece in 2000 and a PhD from the University of Cambridge, UK in 2011. He completed general medicine residency and medical oncology fellowship training in Cambridge and London, UK before moving to the University of Texas MD Anderson Cancer Center in 2013, where he is currently a Tenure-Track Assistant Professor (Physician Scientist) in the Department of Thoracic/Head and Neck Medical Oncology. Dr Skoulidis’ laboratory is focused on (a) unraveling the molecular and clinical heterogeneity of KRAS-mutant non-small cell lung cancer (NSCLC) and developing novel therapeutic strategies to target KRAS-mutant lung tumors and (b) elucidating the impact of individual somatic genomic alterations on the NSCLC immune contexture and immunotherapy response, with the goal of developing novel precision oncogenotype-tailored immunotherapeutic strategies. Dr Skoulidis has received a number of awards for his research including a 2019 AACR NextGen Star award. His work has been published in high impact scientific journals including Cancer Discovery, Cancer Cell, Nature Reviews Cancer and his research has attracted research funding from the Cancer Prevention and Research Institute of Texas, the US Department of Defense and the NIH.
Published in
Speakers
Dr. Harpreet Singh is the Director of the Division of Oncology 2 in the Office of Oncology Diseases, as well the Acting Associate Director for Cancer in Older Adults and Special Populations in the Oncology Center of Excellence at the US FDA.
Dr. Singh received her M.D. degree from the University of Southern California. She completed her Internal Medicine residency and Geriatrics fellowship at USC, followed by a Medical Oncology fellowship at the National Cancer Institute.
FDA Guidance of Industry on Inclusion of Older Adults in Cancer Clinical Trials.
As Director of the Division of Oncology 2, Dr. Singh oversees drug development for lung cancer, head and neck cancer, neurologic tumors, pediatric solid tumors, and rare cancers. Her scope of expertise includes precision medicine and targeted therapy, novel trial design, innovative regulatory initiatives designed to expedite drug approvals, and use of real world data in regulatory decision making. Recent notable approvals in lung cancer include targeted therapies for MET exon 14 skipping mutations and RET fusions. In her role as AD for Cancer in Older Adults, Dr. Singh leads multiple OCE efforts to advance drug development and regulatory science for older adults with cancer and special populations. Dr. Singh has expertly engaged with the greater scientific community, to increase the evidence base for treating older adults with cancer. She has consistently presented her FDA research on this topic at major academic conferences, and published in peer reviewed journals such as the Journal of Clinical Oncology (JCO). Most recently, she spearheaded an She serves as the lead for OCE
Published in
Speakers
Yu Shyr received his Ph.D. in biostatistics from the University of Michigan (Ann Arbor) in 1994 and subsequently joined the faculty at Vanderbilt University School of Medicine. Dr. Shyr is a Fellow of the American Statistical Association (ASA), an elected fellow of the American Association for the Advancement of Science (AAAS) and a US Food and Drug Administration (FDA) advisory committee voting member. He has published more than 480 peer-reviewed papers in a variety of journals (h-index = 104). Dr. Shyr was the member of the US National Academy of Medicine (IOM) Committee on Policy Issues in the Clinical Development of Biomarkers for Molecularly Targeted Therapies. He has served as a member of the US National Cancer Institute (NCI) Developmental Therapeutics Study Section, Cancer Immunopathology and Immunotherapy Study Section and the Population and Patient-oriented Training Study Section. Dr. Shyr was the co-course director for the AACR/ASCO Methods in Clinical Cancer Research Vail Workshop. He is the Associate Editor for JAMA Oncology, and Journal of Thoracic Oncology (JTO). Dr. Shyr’s current research interests focus on developing statistical bioinformatic methods for analyzing next-generation sequencing data based on single cell technology and novel statistical methods for analyzing the ICI survival data.
Published in
Speakers
Leo Shunyakov, MD, is hematology and oncology medical director at Central Care Cancer Center in Bolivar, Missouri. Dr Shunyakov earned his medical degree from the Urals Medical Academy in Yekaterinburg, Russia. He then completed a fellowship in hematology/oncology at University of Rochester, Rochester, NY. Dr Shunyakov is an active researcher with interests including hematology/oncology, biological cancer treatments, as well as chemotherapy and nonchemotherapy cancer treatments.
Published in
Speakers
Dr. Elaine Shum is an Assistant Professor at NYU Langone Health’s Perlmutter Cancer Center. She received her medical degree from Stony Brook University School of Medicine and completed her hematology and oncology fellowship at Albert Einstein College of Medicine/Montefiore Medical Center. At Perlmutter Cancer Center, Dr. Shum treats patients with lung cancer and other thoracic malignancies and is an active member of the Phase I group. She serves as the principal investigator of several thoracic malignancy and Phase I clinical trials at NYU.
Published in
Speakers
Assistant Professor of Medicine and Clinical Director, Thoracic Medical Oncology, Columbia University Medical Center
Published in
Speakers
Frances A. Shepherd, OC, OOnt, MD, FRCPC, FASCO, LLD (Hon)
Dr. Shepherd received her medical degree from the University of Toronto, and currently is a Physician at Princess Margaret Cancer Centre, Toronto, where she holds the Scott Taylor Chair in Lung Cancer Research. She is a University Professor of Medicine at the University of Toronto. She chaired the Lung Cancer Committee of the National Cancer Institute of Canada Clinical Trials Group for 19 years and was IASLC President 2003-to 2005. She has been a member of the ASCO and EORTC Boards of Directors She received the Jacqueline Seroussi Award for Cancer Research (Israel, 2004); the NCI Canada Warwick Award for Research Excellence (2006); the IASLC Research Award (2007); the Ontario Premier’s Summit Research Award (2009); and a Boehringer-Ingelheim Innovation Award (2010). In 2012, she won the British Thoracic Oncology Group International Award, the Royal College of Physicians and Surgeons of Canada Whiteman Award, a Queen Elizabeth II Diamond Jubilee medal and Giants of Cancer Care Award. She received the Order of Ontario (2007); Officer of the Order of Canada (2017), and a Gairdner-Wightman award (2018). She has honourary doctorates from York University (2019) and Faculty of Medicine University of Ottawa (2019). Dr Shepherd’s clinical trials have changed treatment and outcomes for patients with lung cancer at a global level. She has mentored more than 45 post-doctoral research students from around the world, and authored or co-authored more than 550 publications and 35 book chapters.
Dr. Shepherd received her medical degree from the University of Toronto, and currently is a Physician at Princess Margaret Cancer Centre, Toronto, where she holds the Scott Taylor Chair in Lung Cancer Research. She is a University Professor of Medicine at the University of Toronto. She chaired the Lung Cancer Committee of the National Cancer Institute of Canada Clinical Trials Group for 19 years and was IASLC President 2003-to 2005. She has been a member of the ASCO and EORTC Boards of Directors She received the Jacqueline Seroussi Award for Cancer Research (Israel, 2004); the NCI Canada Warwick Award for Research Excellence (2006); the IASLC Research Award (2007); the Ontario Premier’s Summit Research Award (2009); and a Boehringer-Ingelheim Innovation Award (2010). In 2012, she won the British Thoracic Oncology Group International Award, the Royal College of Physicians and Surgeons of Canada Whiteman Award, a Queen Elizabeth II Diamond Jubilee medal and Giants of Cancer Care Award. She received the Order of Ontario (2007); Officer of the Order of Canada (2017), and a Gairdner-Wightman award (2018). She has honourary doctorates from York University (2019) and Faculty of Medicine University of Ottawa (2019). Dr Shepherd’s clinical trials have changed treatment and outcomes for patients with lung cancer at a global level. She has mentored more than 45 post-doctoral research students from around the world, and authored or co-authored more than 550 publications and 35 book chapters.
Published in
Speakers
Dr. Sequist is originally from Michigan and studied chemistry at Cornell University. She received her MD from Harvard Medical School and trained in internal medicine at the Brigham and Women’s Hospital and in hematology/oncology at the Dana-Farber Cancer Institute, where she also received an MPH from the Harvard School of Public Health. She joined the faculty at the Massachusetts General Hospital Cancer Center in 2005 and has an active clinical and translational research career, as well as a busy practice caring for patients with lung cancer. She is currently the Landry Family Professor of Medicine at Harvard Medical School and the Director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital. She has held grants from the NIH, the DOD, and many private foundations. Dr. Sequist’s research focuses on studying targeted therapeutics for lung cancer and bringing new non-invasive tests like circulating tumor cells and circulating tumor DNA to treat and detect lung cancer. In her free time, she likes to spend time with her husband, two sons and her dog, and is a hockey and dance mom.
Published in
Speakers
